Literature DB >> 6434006

Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma.

E K Kruithof, C Tran-Thang, A Ransijn, F Bachmann.   

Abstract

This report describes a plasmatic, fast-acting, specific inhibitor (antiactivator) of tissue-type plasminogen activator (t-PA) and urokinase (UK). After addition of t-PA to human plasma, biexponential decay of activity occurred. The initial rapid inhibition of t-PA activity (half-life of approximately one minute) was correlated with the formation of a complex of a molecular weight of 110,000, suggesting a molecular weight in the order of 40,000 for the antiactivator. Diisopropylfluorophosphate (DFP)-inactivated t-PA did not form complexes with antiactivator. The second-order rate constant for the interaction of t-PA with antiactivator is in the order of 10(7) mol/L-1 sec-1. In plasma, UK added at low concentrations rapidly formed complexes of a mol wt of 95,000. Preincubation of the plasma with t-PA prevented complex formation of UK, and vice versa, suggesting that the same inhibitor inactivates both t-PA and UK. After exhaustion of the antiactivator, t-PA and UK formed complexes with alpha 2-antiplasmin and C1'-inhibitor at a low rate.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6434006

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  42 in total

1.  Butyrate stimulates tissue-type plasminogen-activator synthesis in cultured human endothelial cells.

Authors:  T Kooistra; J van den Berg; A Töns; G Platenburg; D C Rijken; E van den Berg
Journal:  Biochem J       Date:  1987-11-01       Impact factor: 3.857

Review 2.  Streptokinase--the drug of choice for thrombolytic therapy.

Authors:  Adinarayana Kunamneni; Thaer Taleb Abed Abdelghani; Poluri Ellaiah
Journal:  J Thromb Thrombolysis       Date:  2007-02       Impact factor: 2.300

3.  Distribution of plasminogen activator inhibitor (PAI-1) in tissues.

Authors:  A J Simpson; N A Booth; N R Moore; B Bennett
Journal:  J Clin Pathol       Date:  1991-02       Impact factor: 3.411

4.  The mechanism of the reaction between human plasminogen-activator inhibitor 1 and tissue plasminogen activator.

Authors:  T L Lindahl; P I Ohlsson; B Wiman
Journal:  Biochem J       Date:  1990-01-01       Impact factor: 3.857

5.  cDNA cloning of human plasminogen activator-inhibitor from endothelial cells.

Authors:  D Ginsburg; R Zeheb; A Y Yang; U M Rafferty; P A Andreasen; L Nielsen; K Dano; R V Lebo; T D Gelehrter
Journal:  J Clin Invest       Date:  1986-12       Impact factor: 14.808

6.  Plasminogen activator inhibitor is associated with the extracellular matrix of cultured bovine smooth muscle cells.

Authors:  B S Knudsen; P C Harpel; R L Nachman
Journal:  J Clin Invest       Date:  1987-10       Impact factor: 14.808

7.  Recombinant plasminogen activator inhibitor-1 reverses the bleeding tendency associated with the combined administration of tissue-type plasminogen activator and aspirin in rabbits.

Authors:  D E Vaughan; P J Declerck; M De Mol; D Collen
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

8.  Testosterone upregulation of tissue type plasminogen activator expression in Sertoli cells : tPA expression in Sertoli cells.

Authors:  Jian Guo; Yu-Qiang Shi; Wei Yang; Yin-Chuan Li; Zhao-Yuan Hu; Yi-Xun Liu
Journal:  Endocrine       Date:  2007-10-09       Impact factor: 3.633

9.  In vivo distribution of Tc-99m labeled recombinant tissue-type plasminogen activator in control and thrombus-bearing rats.

Authors:  E Tsukamoto
Journal:  Ann Nucl Med       Date:  1992-08       Impact factor: 2.668

10.  Impact of the -675 4G/5G polymorphism of the plasminogen activator inhibitor-1 gene on childhood IgA nephropathy.

Authors:  Su-Ryun Han; Cheon-Jong Kim; Byung-Cheol Lee
Journal:  Exp Ther Med       Date:  2012-01-30       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.